Ziad Ali, MD, detailed two studies he presented on coronary intravascular lithotripsy at TCT 2023 in San Francisco.

Asian patients are rarely represented in large TAVR trials, the authors wrote, so they focused on nearly 1,200 patients from South Korea to provide a fresh perspective. 

A pharmacy benefit management company founded less than five years ago is teaming up with a drug pricing disrupter that will mark its second birthday next month.

More than two-thirds of hospital executives, 70%, say their institution has a formal or comprehensive strategy in place for selecting, acquiring and integrating digital health products.

A hybrid approach may increase the risk of certain adverse events, according to a new meta-analysis focused on long-term outcomes. 

Abbott's HeartMate 3 LVAD is the only FDA-approved device of its kind currently available in the United States. Should reports of adverse events worry cardiologists? Or are they to be expected when treating such a vulnerable patient population?

This small, low-cost practice change is a promising way to increase cancer screening participation, researchers detailed recently. 

While GLP-1 drugs were originally developed to treat diabetes, researchers keep finding additional ways these medications can potentially benefit patients.